BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

April 26, 2017
Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors originally developed as cancer treatments to create a drug that can tackle all known and likely future strains of the influenza virus.
Previous Video
BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development
BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development

What kinds of partnerships are key to getting rare disease research out of the lab and to patients as thera...

Next Video
BIO-Europe Spring® 2017: Venneos develops next generation label-free cell analysis
BIO-Europe Spring® 2017: Venneos develops next generation label-free cell analysis

Cell-based assays play a crucial role in drug discovery, toxicity testing and have the potential to contrib...